Drug Profile
Research programme: infectious keratoconjunctivitis nanoparticle therapies - NanoViricides
Alternative Names: EkC-Cide™; EKC-Cide™-ILatest Information Update: 26 Jul 2019
Price :
$50
*
At a glance
- Originator NanoViricides
- Developer Keio University School of Medicine; NanoViricides
- Class Antivirals; Polymers
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infectious keratoconjunctivitis
Most Recent Events
- 26 Jul 2019 No development reported - Preclinical for Infectious keratoconjunctivitis in USA (Ophthalmic)
- 09 Apr 2019 NanoViricides expects to submit documents regarding pre-IND meeting to US FDA, by April 2019
- 09 Apr 2019 NanoViricides plans to initiate GLP safety and toxicology study in USA, in the second week of May 2019